Operates as a single-segment specialty chemicals business, with FY26 revenue from operations of Rs 218.60 cr and total assets of Rs 659.94 cr. In Q1 FY27, revenue from operations reached Rs 83.55 cr, up 49.5% from Rs 55.88 cr in the same quarter a year earlier, while profit after tax rose to Rs 15.10 cr from Rs 12.03 cr. The cost structure is dominated by other operating expenses at 33.1% of revenue and materials at 26.2%, with employee costs at 18.2% and depreciation at 9.8%. Capital expenditure absorbs a notably high 40.3% of revenue, signalling an asset-heavy expansion mode relative to current turnover. The company sits within the Alembic group, with promoter/promoter-group entities including Alembic Pharmaceuticals Ltd and Shreno entities. An earlier share sub-division and 3-for-1 bonus issue were completed in October 2025, and a final dividend for FY26 was declared at the 53rd AGM, payable on or from 3 August 2026. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Specialty chemicals (100%). Single-segment, asset-heavy specialty chemicals (FY26 capex 40.3% of revenue)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 150 | 212 | 206 | 211 | 219 |
| EBITDA (ex other income) | 54 | 77 | 64 | 60 | 61 |
| margin % | 36.1 | 36.2 | 31.3 | 28.3 | 27.8 |
| Owners' profit | 38 | 54 | 54 | 49 | 39 |
| EPS, as reported (₹) | 122.03 | 175.22 | 176.35 | 160.21 | 15.95 |
| ROE % · ROCE % | 12.3 · 14.8 | 15.3 · 18.5 | 13.3 · 15.6 | 10.6 · 11.2 | 8.0 · 8.7 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.05 | 0.16 |
| Cash from operations | 44 | 43 | 56 | 38 | 54 |
| Capex | (48) | (17) | (39) | (160) | (88) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 57 | 49 | 52 | 56 | 59 | 49 | 55 | 84 |
| Profit before tax | 17 | 17 | 12 | 16 | 11 | 7 | 16 | 19 |
| Net profit | 14 | 15 | 10 | 12 | 9 | 6 | 13 | 15 |
| EPS (₹) | 46.09 | 49.51 | 31.16 | 39.04 | 27.94 | 2.50 | 5.07 | 6.13 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 12 Aug 2026 · Newspaper ad on special window for physical shares dematerialisation | compliance | minimal | — | — |
| 31 Jul 2026 · Paushak Limited shares Q1 FY27 results via newspaper publication | compliance | minimal | — | — |
| 30 Jul 2026 · Paushak 53rd AGM: Dividend, Director Re-appointment and Commission Approved | board shareholder meetings | low | — | — |
| 30 Jul 2026 · Paushak 53rd AGM held on 30 July 2026 via video conferencing | board shareholder meetings | low | — | — |
| 30 Jul 2026 · Paushak 53rd AGM: All 5 resolutions approved with 99.99% support | board shareholder meetings | low | — | — |
| 30 Jul 2026 · Paushak Q1 FY27 PAT up 25.5% YoY to Rs 15.1 cr, revenue jumps 49.5% | results | high | — | — |
| 30 Jul 2026 · Paushak Q1 FY27 PAT up 25.5% YoY to Rs 15.1 cr, revenue jumps 49.5% | results | high | — | — |
| 30 Jul 2026 · Q1 FY27 results - Revenue up 49 percent, PAT up 26 percent YoY | results | high | — | — |
| 21 Jul 2026 · Board meeting on 30 July to consider Q1 FY27 unaudited results | results | low | — | — |
| 7 Jul 2026 · Certificate under SEBI Depositories Regulations 74(5) for Apr-Jun 2026 quarter | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| AETHER INDUSTRIES LIMITED |
| 22,229 |
| 94.3 |
| 9.05 |
| 60.4 |
| 8.9 |
| 11.4 |
| — |
| 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD | 18,401 | 23.1 | 2.92 | 14.9 | 10.9 | 13.3 | 10.9 | 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 17.5 | 23.4 | 33 of 103 | 69% |
| P/B | 3.6 | 2.9 | 64 of 99 | 36% |
| ROCE | 8.5 | 10.3 | 60 of 108 | 45% |
| ROE | 8.0 | 8.1 | 52 of 101 | 49% |
| Debt / Equity | 0.2 | 0.2 | 49 of 101 | 52% |
| EBITDA margin | 34.5 | 15.5 | 6 of 99 | 95% |
| Revenue growth | 49.5 | 24.4 | 17 of 94 | 83% |
| Profit growth | 25.5 | 55.1 | 57 of 92 | 39% |
| Market cap | 1795 | 732 | 39 of 107 | 64% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
